tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Editas Medicine reports Q2 EPS (63c), consensus (38c)
PremiumThe FlyEditas Medicine reports Q2 EPS (63c), consensus (38c)
16d ago
Editas Medicine Unveils Promising Gene Editing Data
Premium
Company Announcements
Editas Medicine Unveils Promising Gene Editing Data
3M ago
Promising Outlook for Editas Medicine: Strong Preclinical Data and Projected Financial Success
Premium
Ratings
Promising Outlook for Editas Medicine: Strong Preclinical Data and Projected Financial Success
3M ago
Promising Preclinical Data and Market Opportunities Drive Buy Rating for Editas Medicine
PremiumRatingsPromising Preclinical Data and Market Opportunities Drive Buy Rating for Editas Medicine
3M ago
Editas Medicine Reports Q1 2025 Progress and Financials
Premium
Company Announcements
Editas Medicine Reports Q1 2025 Progress and Financials
4M ago
Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs
Premium
The Fly
Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs
4M ago
Editas Medicine: Hold Rating Amid Legal Uncertainty and Financial Concerns
PremiumRatingsEditas Medicine: Hold Rating Amid Legal Uncertainty and Financial Concerns
4M ago
Buy Rating for Editas Medicine: Promising Advancements in In Vivo Gene Editing
Premium
Ratings
Buy Rating for Editas Medicine: Promising Advancements in In Vivo Gene Editing
4M ago
Editas Medicine reports Q1 EPS (92c), consensus (59c)
Premium
The Fly
Editas Medicine reports Q1 EPS (92c), consensus (59c)
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100